Cannabidiol (Epidyolex®, GW CBD) is indicated for use as an adjunctive therapy, in conjunction with clobazam, for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients ≥2 years of age.1 Here we present a webinar discussion and summary on the shared experiences of six leading physicians on the use of GW CBD for treating these rare epilepsies.

EXPERT PERSPECTIVES

Prof. Dr Eizabeth
Thiele
Prof. Dr Selim
Benbadis
Prof. Dr Bernhard
Steinhoff
Prof. Dr Andreas
Schulze-Bonhage
Prof. Dr Ulrich
Brandl
Prof. Dr Angela
Kaindl

PROFESSOR DR ELIZABETH THIELE

Massachusetts General Hospital, Boston, MA, USA

Elizabeth Thiele is Director of the Pediatric Epilepsy Service at Massachusetts General Hospital, Boston, MA, USA, and is Professor of Neurology at the Harvard Medical School. She organised and established the Herscot Center for Tuberous Sclerosis Complex and a ketogenic diet clinic to treat and manage patients with epilepsy.

Disclosures

Consultant for GW Pharmaceuticals, Zogenix, Biocodex, Aquestive, West Therapeutics, RegenexBio. Research grants from GW Pharmaceuticals, Zogenix.

Overview

Elizabeth Thiele provides an overview of the diverse patient profiles of individuals with epilepsy who may benefit from GW CBD treatment, and how to initiate and escalate dosing, and manage adverse events.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR SELIM BENBADIS

University of South Florida, Tampa, USA

Selim Benbadis is Professor of Neurology at the University of South Florida and is Director of the University of South Florida/Tampa General Hospital Comprehensive Epilepsy Program. He has authored more than 100 articles and book chapters and serves on several editorial boards.

Disclosures

Consultant for Brain Sentinel, Cavion, Ceribell, Eisai, Greenwich, LivaNova, NeuroPace, SK Biopharmaceuticals, Sunovion. Speakers’ bureau for Eisai, Greenwich, LivaNova, Sunovion. National Medical Director for RSC Diagnostic Services (EEG). Florida Medical Director of Stratus/Alliance (EEG). Member of Epilepsy Study Consortium. Grant support from Cavion, LivaNova, Greenwich, SK Biopharmaceuticals, Sunovion, Takeda, Xenon. Royalties as an author or editor for eMedicine-Medscape-WebMD, UpToDate. Editorial board for Epilepsy.com (Epilepsy Foundation) controversy section, eMedicine-Medscape-WebMD, Epileptic Disorders, Epilepsy and Behavior, Expert Review of Neurotherapeutics.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR BERNHARD STEINHOFF

University of Freiburg, Freiburg im Breisgau, Germany

Bernhard Steinhoff is Professor of Neurology and Clinical Neurophysiology at the University of Freiburg and is Medical Director of the Epilepsy Centre Kork. He is a past president of the German Society of Epileptology and author of numerous peer-reviewed papers and book articles.

Disclosures

Speaker honoraria from Al-Jazeera, Desitin, Eisai, GW Pharmaceuticals, Hikma, Novartis, Sandoz, UCB. Advisory boards or consultancy agreements from Arvelle, Bial, B. Braun, Desitin, Eisai, GW Pharmaceuticals, UCB.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR ANDREAS SCHULZE-BONHAGE

University Hospital Freiburg, Freiburg im Breisgau, Germany

Professor Andreas Schulze-Bonhage is Medical Director at the Freiburg Epilepsy Center, University of Freiburg, and President of the German Society of Epileptology. He is author of more than 340 peer-reviewed publications, has been active as a Principal Investigator in 40 multicentre clinical trials, and receives research funding from the EU, German Federal Ministry of Education and Research (BMBF), Deutsche Forschungsgemeinschaft, and the National Institutes of Health.

Disclosures

Research support from Bial, BMBF, DFG, EU, HBP, NIH. Honoraria for lectures or advice from Arvelle, Bial, Eisai, GW Pharmaceuticals, UCB.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR ULRICH BRANDL

University Hospital Jena, Jena, Germany

Professor Ulrich Brandl is Director of the Department of Neuropaediatrics, University Hospital Jena, Germany, where he also serves as Chairman of the Ethics Committee

Disclosures

Honoraria for presentations, lectures, or advisory boards from Bial, Desitin, Eisai, GW Pharmaceuticals, UCB, Zogenix.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR ANGELA KAINDL

Charité – Universitätsmedizin Berlin, Berlin, Germany

Professor Angela M. Kaindl is Director of the Department of Pediatric Neurology and the Center for Chronically Sick Children at Charité – Universitätsmedizin Berlin. She is also Principal Investigator at the Charité Institute of Cell Biology and Neurobiology.

Disclosures

Speaker honoraria from GW Pharmaceuticals.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported to GW Pharma on medinfo@gwpharm.com

EXPERT PERSPECTIVES

Prof. Dr Eizabeth
Thiele
Prof. Dr Selim
Benbadis
Prof. Dr Bernhard
Steinhoff
Prof. Dr Andreas
Schulze-Bonhage
Prof. Dr Ulrich
Brandl
Prof. Dr Angela
Kaindl

PROFESSOR DR ELIZABETH THIELE

Massachusetts General Hospital, Boston, MA, USA

Elizabeth Thiele is Director of the Pediatric Epilepsy Service at Massachusetts General Hospital, Boston, MA, USA, and is Professor of Neurology at the Harvard Medical School. She organised and established the Herscot Center for Tuberous Sclerosis Complex and a ketogenic diet clinic to treat and manage patients with epilepsy.

Disclosures

Consultant for GW Pharmaceuticals, Zogenix, Biocodex, Aquestive, West Therapeutics, RegenexBio. Research grants from GW Pharmaceuticals, Zogenix.

Overview

Elizabeth Thiele provides an overview of the diverse patient profiles of individuals with epilepsy who may benefit from GW CBD treatment, and how to initiate and escalate dosing, and manage adverse events.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR SELIM BENBADIS

University of South Florida, Tampa, USA

Selim Benbadis is Professor of Neurology at the University of South Florida and is Director of the University of South Florida/Tampa General Hospital Comprehensive Epilepsy Program. He has authored more than 100 articles and book chapters and serves on several editorial boards.

Disclosures

Consultant for Brain Sentinel, Cavion, Ceribell, Eisai, Greenwich, LivaNova, NeuroPace, SK Biopharmaceuticals, Sunovion. Speakers’ bureau for Eisai, Greenwich, LivaNova, Sunovion. National Medical Director for RSC Diagnostic Services (EEG). Florida Medical Director of Stratus/Alliance (EEG). Member of Epilepsy Study Consortium. Grant support from Cavion, LivaNova, Greenwich, SK Biopharmaceuticals, Sunovion, Takeda, Xenon. Royalties as an author or editor for eMedicine-Medscape-WebMD, UpToDate. Editorial board for Epilepsy.com (Epilepsy Foundation) controversy section, eMedicine-Medscape-WebMD, Epileptic Disorders, Epilepsy and Behavior, Expert Review of Neurotherapeutics.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR BERNHARD STEINHOFF

University of Freiburg, Freiburg im Breisgau, Germany

Bernhard Steinhoff is Professor of Neurology and Clinical Neurophysiology at the University of Freiburg and is Medical Director of the Epilepsy Centre Kork. He is a past president of the German Society of Epileptology and author of numerous peer-reviewed papers and book articles.

Disclosures

Speaker honoraria from Al-Jazeera, Desitin, Eisai, GW Pharmaceuticals, Hikma, Novartis, Sandoz, UCB. Advisory boards or consultancy agreements from Arvelle, Bial, B. Braun, Desitin, Eisai, GW Pharmaceuticals, UCB.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR ANDREAS SCHULZE-BONHAGE

University Hospital Freiburg, Freiburg im Breisgau, Germany

Professor Andreas Schulze-Bonhage is Medical Director at the Freiburg Epilepsy Center, University of Freiburg, and President of the German Society of Epileptology. He is author of more than 340 peer-reviewed publications, has been active as a Principal Investigator in 40 multicentre clinical trials, and receives research funding from the EU, German Federal Ministry of Education and Research (BMBF), Deutsche Forschungsgemeinschaft, and the National Institutes of Health.

Disclosures

Research support from Bial, BMBF, DFG, EU, HBP, NIH. Honoraria for lectures or advice from Arvelle, Bial, Eisai, GW Pharmaceuticals, UCB.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR ULRICH BRANDL

University Hospital Jena, Jena, Germany

Professor Ulrich Brandl is Director of the Department of Neuropaediatrics, University Hospital Jena, Germany, where he also serves as Chairman of the Ethics Committee

Disclosures

Honoraria for presentations, lectures, or advisory boards from Bial, Desitin, Eisai, GW Pharmaceuticals, UCB, Zogenix.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to GW Pharma on medinfo@gwpharm.com

PROFESSOR DR ANGELA KAINDL

Charité – Universitätsmedizin Berlin, Berlin, Germany

Professor Angela M. Kaindl is Director of the Department of Pediatric Neurology and the Center for Chronically Sick Children at Charité – Universitätsmedizin Berlin. She is also Principal Investigator at the Charité Institute of Cell Biology and Neurobiology.

Disclosures

Speaker honoraria from GW Pharmaceuticals.

Prescribing Information

Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to GW Pharma on medinfo@gwpharm.com

MEETING HIGHLIGHTS

Epilepsy FOCUS: Shared experience of cannabidiol

In this webinar, six leading experts discuss case studies of patients treated with GW CBD, including patient profiles, and how to initiate and escalate GW CBD dosing. The management of adverse events and patients with previous experience of non-regulatory approved cannabis-based products is also considered.

Welcome and introductions GW CBD patient profile Starting and maintaining patients on GW CBD Managing adverse events GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products

For additional resources and patient cases, please visit the GW Pharmaceuticals Epilepsy Focus site

Meeting Report

Download a brief written report of the meeting.